Mycophenolate Mofetil Capsule
FDA Label NDC 0093-7334

60 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Mycophenolate Mofetil (NDC 0093-7334). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: embryofetal toxicity, malignancies, and serious infections, 1 indications and usage, 2.1 important administration instructions, 2.2 dosage recommendations for kidney transplant patients, 2.3 dosage recommendations for heart transplant patients, 2.4 dosage recommendations for liver transplant patients, 2.5 dosage modifications: patients with renal impairment, neutropenia, 3 dosage forms and strengths, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.